Clarion Crivicin Griseofulvin Tablets

CRIVICIN GRISEOFULVIN TABLET B.P. 500 mg

 

COMPOSITION

Each uncoated tablet contains

Griseofulvin B.P. 500mg

 

PROPERTIES

CRIVICIN-500 is an fungistatic antibiotic derived from a specie of penicillium and used for the treatment of superficial mycosis.

CRIVICIN-500 is active in vitro against various species of microsporum, Epiderniophyton and Trichophyton. It has no effect on bacteria or another genera of fungi, such as candida albicans (‘thrush fungus’); Aspergillas and Malassezia furfur (pityriasis Versicolor).

CRIVICIN-500 is deposited in the keratin precursor cells and has a greater affinity for diseased tissues. It enables newly-formed keratin of the skin, hair and nails to resist attack by fungi.

 

INDICATIONS

CRIVICIN-500 is effective against the dermatophytes causing ringworm (tinea) infection of the skin, hair and nails including microsporum canis, Trichophyton rubrum and T. Verucosum. It is generally given for such infections that involve the scalp, hair, nails and skin and which do not respond to topical treatment.

 

DOSAGE AND ADMINISTRATION

Dosage should be taken after meals, otherwise absorption is likely to be inadequate.

Adults

Normally 500-1000 mg (1-2 tablets) daily, but not less than 10 mg/kg body weight daily. A single dose daily is often satisfactory but divided doses may be more effective in patients who respond poorly.

Children

Usually 10mg/kg body weight daily in divided doses.

The duration of treatment depends upon the thickness of keratin at the site of infection. 2-6 weeks for infection of hair and skin, 6-9 months for infections of the finger nails and 12-18 months for the infection of the toe nails.

 

CONTRA INDICATIONS

CRIVICIN-500 is contraindicated in patients with porphyria, liver failure, and in individuals with history of hypersensitivity to Griseofulvin.

 

PRECAUTIONS

Concurrent treatment with CRIVICIN-500 may reduce the effectiveness of oral contraceptives, so additional contraceptive precautions should be taken during CRIVICIN-500 treatment and for a month after stopping it. As there is no evidence of its safety in human pregnancy (Griseofulvin is teratogenic in animals and some case reports suggest that it produces human foetal abnormalities). CRIVICIN-500 should not be used during pregnancy.

Griseofulvin decreases the activity of warfarin-type anticoagulants so that patients receiving these drugs concomitantly may require dosage adjustment of the anticoagulant during and after CRIVICIN-500 therapy.

Barbiturates usually depress Griseofulvin activity and concomitant administration may require a dosage adjustment of the antifungal agent.

Potentiates alcohol, effect producing effect like trachycardia and flush.

 

ADVERSE REACTIONS

When adverse reactions occur, they are most commonly of the hypersensitivity type such as skin rashes, urticaria and rarely angioneurotic edema.

Other side effects, reported occasionally, are gastric discomfort, headache, dizziness and insomnia, dryness of the mouth, an altered sensation of taste. Proteinuria and leucopenia have been reported rarely. Administration of the drug should be discontinued if granulocy topenia occurs.

 

STORAGE

STORE IN COOL DRY PLACE.

PROTECT FROM DIRECT LIGHT.

KEEP ALL MEDICINE OUT OF REACH OF CHILDREN.

 

PRESENTATION

CRIVICIN-500 tabs are supplied in Blister pack of 20 Tablets.

 

NAFDAC Reg. No.: A4-6246

 

Manufactured in China by

Nantong Jinghua Pharmaceutical Co, Ltd.

9 Xingtai Road, Gangzha Zone Nantong Jiangsu China 226005

 

Marketed by

CLARION MEDICALS LTD.

23, Afolabi Lesi Street, llupeju,

Lagos, Nigeria.

Biomeovin Griseofulvin Tablet BP 500mg

BIOMEOVIN® 500
(Griseofulvin Tablet BP 500mg)

Medical Information. To be read carefully.

Each uncoated tablet contains: Griseofulvin BP 500 mg

 

PROPERTIES

BIOMESOVIN is an oral fungistatic antibiotic derived from a species of Penicillium and used for the treatment of superficial mycoses.

BIOMESOVIN is active in vitro against various species of Microsporum, Epidermophyton and Trichophyton.

It has no effect on bacteria or on other genera of fungi, such as Candida albicans (“thrush fungus”), Aspergilus and Malassezia furfur (Pityriasis versicolor).

BIOMESOVIN is deposited in the keratin precursor cells and has a greater affinity for diseased tissues. It enables newly-formed keratin of the skin, hair and nails to resist attack by fungi.

 

INDICATIONS

BIOMESOVIN is effective against the dermatophytes causing ringworm (tinea) infections of the skin, hair and nails including Microsporum canis, Trichophyton rubrum and T. verrucosum.

 

DOSAGE AND MODE OF ADMINISTRATION

Doses should be taken after meals, otherwise absorption is likely to be inadequate.

Adults: normally 500 to 1,000 mg daily, but not less than 10 mg/kg body weight daily.
A single dose daily is often satisfactory but divided doses may be more effective in patients who respond poorly.

Children: usually 10 mg per kg body weight daily in divided doses.
The duration of treatment depends upon the thickness of keratin at the site of infection. For hair or skin at least four weeks’ treatment is required whereas toe or finger nails may need six to twelve months’ treatment.

Therapy should be continued for at least two weeks after all signs of infection have disappeared.

or as directed by the physician.

 

CONTRAINDICATIONS

BIOMESOVIN is contraindicated in patients with porphyria, hepatocellular failure and in individuals with a history of hypersensitivity to griseofulvin.

 

PRECAUTIONS

– Concurrent treatment with griseofulvin may reduce the effectiveness of oral contraceptives, so additional contraceptive precautions should be taken during BIOMESOVIN treatment and for a month after stopping it.

– As there is no evidence of its safety in human pregnancy (griseofulvin is teratogenic in animals and some case-reports suggest that it produces human foetal abnormalities), BIOMESOVIN should not be used in pregnancy.

– Biomesovin decreases the activity of warfarin-type anticoagulants so that patients receiving these drugs concomitantly may require dosage adjustment of the anticoagulant during and after BIOMESOVIN therapy.

– Barbiturates usually depress griseofulvin activity and concomitant administration may require a dosage adjustment of the antifungal agent.

– The effect of alcohol may be potentiated by griseofulvin, producing such effects as tachycardia and flush.

 

ADVERSE REACTIONS

– When adverse reactions occur, they are most commonly of the hypersensitivity type such as skin rashes, urticaria and rarely angioneurotic edema.

– Other side effects, reported occasionally, are gastric discomfort, headache, dizziness and insomnia.

– Proteinuria and leukopenia have been reported rarely. Administration of the drug should be discontinued if granulocytopenia occurs.

 

STORAGE AND VALIDITY

Store away from light and in a cool dry place.

Do not exceed the expiry date mentioned on the package.

The drug shall only be dispensed by or on the prescription of a physician.

 

KEEP OUT OF REACH OF CHILDREN.

 

PRESENTATION

BIOMESOVIN Tablets are supplied in packs of 20 and 250 tablets.

 

MANUFACTURED BY

Bharat Parenterals Ltd.

Vill. Haripura, Ta. Savli, Dist.

Vadodara – 391 520, Gujarat, India.
 

Manufactured For:

BIOMEDICINE S.P.N.L.

No 16 Anionwu Street Odoakpu

P.O. Box 7846 Onitsha, Nigeria.

Sckivspharm@yahoo.com

Bicoten Dexamethasone Clotrimazole and Gentamicin Cream

BIOCOTEN® Cream

BIOCOTEN combines the anti-inflammatory and antipruritic effect of Dexamethasone, the antimycotic/antibacterial activity of Clotrimazole and the broad spectrum antibacterial activity of Gentamicin in a well formulated cream base.

 

COMPOSITION

20g of cream contains 8.993mg Dexamethasone acetate, corresponding to 8mg Dexamethasone, 200mg Clotrimazole and 20mg Gentamicin as base.

 

ACTIONS

Being a corticosteroid, Dexamethasone has anti-inflammatory, antipruritic and anti-allergic properties. Clotrimazole acts on dermatophytes such as Trichophyton, Microsporium species, on yeast such as Candida species, on mould and other fungi. Gentamicin acts both on gram-positive and gram-negative bacteria. In cases where local action on infecting fungi or bacteria is required, the anti Inflammatory and antipruritic effect accelerate the improvement of clinical symptoms.

In cases where a local anti-inflammatory and antipruntic effect is required, any infection by fungi or bacteria is at the same time eliminated or prevented.

 

INDICATIONS

Inflammation and infection of the skin, particularly those caused by fungi and/or bacteria such as contact eczema, atopic eczema, seborrhoeal eczema, mycotic eczema, microbial eczema, nummular eczema, eczema in abnormal intestinal flora, intertrigo, non-specific puritus, circumscibed disseminated neurodermatitis, folliculitis, pyodermia, pustular dermatitis, infections secondary to accidental injuries or burns.

 

DOSAGE AND ADMINISTRATION

A sufficient quantity of BIOCOTEN cream is rubbed into the affected skin area after cleansing twice daily, preferably mornings and evenings.

The treatment should be continued for several days after disappearance of symptoms such as itching and burning in order to assure complete eradication of the infection.
In highly acute diseases, the cream can be applied to sterile gauze to maintain contact with the skin as long as possible.

In refractory cases, where no response is seen after treatment for 8-10 days the attending physician must determine the further course of treatment.

 

SIDE EFFECT

Systemic effects need not to be expected following topical application of BIOCOTEN since, even through diseased skin, absorption into the blood stream is minimal, Hypopigmentation, skin atrophy or striae do not follow BIOCOTEN application, since these occur only during long term treatment with preparations containing corticorsteroids.

 

CONTRA-INDICATIONS

Proven intolerance to the individual constituents, Tuberculosis of the skin, Virus infections of the skin, including Vaccinia, Vericella, Herpes simplex.
Occlusive technique in atopic eczema.

 

PRECAUTIONS

Since BIOCOTEN contains Dexamethasone, it should be used with caution in babies and pregnant women.

 

KEEP OUT OF THE REACH OF CHILDREN!

 

STORAGE CONDITION

Store below 30°C. Protect from light.

 

PRESENTATION

Tube of 20g

 

Manufactured by

DRUGFIELD PHARMACEUTICALS LIMITED

Lynson Chemical Avenue, Km 38, Lagos-Abeokuta Expressway,

Sango-Otta, Ogun State, Nigeria.

website: http://www.drugfieldpharma.com

e-mail: info@drugfieldpharma.com